CW2IP2: Imaging and Diagnostic Assessments
NCT06083467
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This current protocol will provide the key data to help determine the specificity of our to-be-developed radiotracers by implementing a multi-site diagnostic assessment core and PET imaging of A-beta amyloid (may be completed at some sites as part of another protocol) that is commonly deposited in the brains of people with Parkinson's Disease (PD), Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP) or Frontotemporal Dementia (FTD) as well as healthy controls.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Tauopathies
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 40 to 85 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- University of Pennsylvania
- Last updated on ClinicalTrials.gov
- January 7, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Pennsylvania · 1
- University of Pennsylvania · Philadelphia, PA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.